Xylometazoline

Evidence Level: L3

Predicted Indications: 1

Xylometazoline

Pharmacist Assessment Report

Xylometazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease

One-Sentence Summary

Xylometazoline is a topical nasal decongestant originally used for pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, with no registered clinical trials but 6 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Pharyngitis, common cold
Predicted New Indication	Nasal cavity disease
TxGNN Prediction Score	0.9991
Evidence Level	L3
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, xylometazoline is an imidazoline-derivative alpha-adrenergic agonist applied to the nasal mucosa. It constricts mucosal blood vessels, which reduces swelling and nasal resistance. Pharmacology records list it as acting on alpha-2A, alpha-2B and alpha-2C adrenoceptors (human), alpha-1D (rat) and a trace amine receptor (mouse). However, affinity data at the human targets were not available, so no primary target has been confirmed.

The original indications (common cold and pharyngitis) already involve nasal congestion and mucosal swelling. A predicted benefit in “nasal cavity disease” is therefore a close neighbour of what the drug already does. This is closer to an indication extension than true repurposing.

The literature supports this link. Studies describe nasal cavity expansion, changes in nasal airflow and resistance, and use as a decongestant to prepare the nose for endoscopy or intubation, including a randomized trial in children.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24158493	2013	RCT (double-blind, placebo-controlled)	JAMA Otolaryngol Head Neck Surg	Intranasal topical anaesthetic and decongestant before flexible nasendoscopy in children, compared with placebo
22427029	2013	Prospective randomized blinded study (100 patients)	Eur Arch Otorhinolaryngol	Cotton pledget packing vs topical spray for nasal preparation before endoscopy
24023995	2013	Clinical study	Korean J Anesthesiol	Xylometazoline spray vs epinephrine gauze for expanding the nasal cavity before nasotracheal intubation
34783482	2021	Review	Vestnik Otorinolaringologii	Nasal mucosa in the elderly and treatment of inflammatory diseases of the nasal cavity and sinuses, including combined decongestant sprays
1281924	1992	Physiological/clinical study	Rhinology	Nasal airflow asymmetry in healthy subjects and in acute rhinitis with the common cold, and the effect of xylometazoline on it
8740084	1996	Double-blind randomized study (18 subjects)	Arzneimittel-Forschung	Tuaminoheptane plus N-acetylcysteine compared with xylometazoline and placebo on nasal resistance (indirect evidence)

India Market Information

Twenty valid single-ingredient registrations were found, all as nasal drops or nasal solution. Approved indication text was not available for these registrations. The five main authorizations are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
247063	Zetowin-A Nasal Solution	Bottle of 10 ml nasal solution	Not available
159626	Nasrea Mini Nasal Drops	Packet of 10 ml nasal drops	Not available
190770	Relinose 0.1% Nasal Drops	Bottle of 10 ml nasal drops	Not available
244932	Xylojeev Nasal Drops	Bottle of 10 ml nasal drops	Not available
169283	Otri-X Nasal Drops	Bottle of 10 ml nasal drops	Not available

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): hypertension and hypertensive disorder, diabetes mellitus, diabetic ketoacidosis, heart disease and cardiovascular disease, hyperthyroidism, Graves disease, and thyrotoxicosis.
Drug Interactions: Five records were found. All are pharmacology records of receptor targets (alpha-1D, alpha-2A, alpha-2B and alpha-2C adrenoceptors, and TAAR4P), not drug-drug interactions with severity grades. General pharmacology also suggests caution with MAO inhibitors and other sympathomimetics.
Use-related cautions (general pharmacology): Prolonged use risks rebound congestion (rhinitis medicamentosa). Caution is needed in young children.

Please also refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence is supportive but limited. It consists of several small or procedural studies, including randomized trials in nasal preparation, with no registered clinical trials. The predicted use sits within or next to the drug’s existing nasal decongestant role, and the drug is widely marketed in India.

To proceed, the following is needed:

Package insert warnings and contraindications from India registrations (currently missing, and a blocking gap for safety screening)
Approved indication text for the registered products
Detailed mechanism of action data (for example, from DrugBank)
Confirmation that the “nasal cavity disease” indication is distinct from the existing common cold indication
A duration-of-use limit and a plan for patients with cardiovascular disease, and for children
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.